Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
Praxis Precision Medicines (NASDAQ: PRAX) has announced its participation in three major investor conferences in November 2024. The company will present at the Truist Securities BioPharma Symposium in New York on November 7 at 9:40am ET, the Guggenheim Securities Inaugural Healthcare Innovation Conference in Boston on November 11 at 1:00pm ET, and the Jefferies London Healthcare Conference in London on November 20-21.
Management will participate in fireside chats at both Truist and Guggenheim events, with the Guggenheim session being available via live webcast. One-on-one meetings will be available at all three conferences. The Guggenheim webcast will be accessible through the company's website for 90 days after the event.
Praxis Precision Medicines (NASDAQ: PRAX) ha annunciato la sua partecipazione a tre importanti conferenze per investitori a novembre 2024. L'azienda presenterà al Truist Securities BioPharma Symposium a New York il 7 novembre alle 9:40 ET, al Guggenheim Securities Inaugural Healthcare Innovation Conference a Boston l'11 novembre alle 13:00 ET, e al Jefferies London Healthcare Conference a Londra dal 20 al 21 novembre.
La direzione parteciperà a discussioni informali sia agli eventi di Truist che di Guggenheim, con la sessione di Guggenheim che sarà disponibile tramite webcast in diretta. Saranno disponibili incontri personali a tutte e tre le conferenze. Il webcast di Guggenheim sarà accessibile attraverso il sito web dell'azienda per 90 giorni dopo l'evento.
Praxis Precision Medicines (NASDAQ: PRAX) ha anunciado su participación en tres importantes conferencias para inversores en noviembre de 2024. La empresa presentará en el Truist Securities BioPharma Symposium en Nueva York el 7 de noviembre a las 9:40 ET, en el Guggenheim Securities Inaugural Healthcare Innovation Conference en Boston el 11 de noviembre a la 1:00 ET, y en el Jefferies London Healthcare Conference en Londres del 20 al 21 de noviembre.
La dirección participará en charlas informales en los eventos de Truist y Guggenheim, siendo la sesión de Guggenheim disponible a través de una transmisión en vivo. Habrá reuniones uno a uno disponibles en las tres conferencias. La transmisión de Guggenheim será accesible a través del sitio web de la empresa durante 90 días después del evento.
프락시스 정밀 의학 (NASDAQ: PRAX)는 2024년 11월에 있을 세 개의 주요 투자자 회의에 참여한다고 발표했습니다. 이 회사는 뉴욕에서 11월 7일 오전 9시 40분 ET에 트루이스트 증권 생명공학 심포지엄에서 발표하고, 보스턴에서 11월 11일 오후 1시에 구겐하임 증권 제1회 헬스케어 혁신 회의에서, 그리고 런던에서 11월 20일부터 21일까지 제프리스 런던 헬스케어 회의에 참석합니다.
경영진은 트루이스트와 구겐하임 행사에서 캐주얼한 대화에 참여하며, 구겐하임 세션은 라이브 웹캐스트로 제공됩니다. 모든 세 회의에서 일대일 회의가 가능합니다. 구겐하임 웹캐스트는 이벤트 후 90일 동안 회사 웹사이트를 통해 접근할 수 있습니다.
Praxis Precision Medicines (NASDAQ: PRAX) a annoncé sa participation à trois grandes conférences pour investisseurs en novembre 2024. L'entreprise présentera au Symposium BioPharma de Truist Securities à New York le 7 novembre à 9h40 ET, à la Conférence Inaugurale sur l'Innovation en Santé de Guggenheim Securities à Boston le 11 novembre à 13h00 ET, et à la Conférence sur la Santé de Jefferies à Londres les 20 et 21 novembre.
La direction participera à des discussions informelles lors des événements de Truist et de Guggenheim, la session de Guggenheim étant disponible par webcast en direct. Des réunions individuelles seront disponibles à toutes les trois conférences. Le webcast de Guggenheim sera accessible via le site web de l'entreprise pendant 90 jours après l'événement.
Praxis Precision Medicines (NASDAQ: PRAX) hat seine Teilnahme an drei bedeutenden Investorenkonferenzen im November 2024 bekannt gegeben. Das Unternehmen wird am 7. November um 9:40 Uhr ET beim Truist Securities BioPharma Symposium in New York, am 11. November um 13:00 Uhr ET beim Guggenheim Securities Inaugural Healthcare Innovation Conference in Boston und am 20. und 21. November beim Jefferies London Healthcare Conference in London präsentieren.
Das Management wird an informellen Gesprächen bei den Veranstaltungen von Truist und Guggenheim teilnehmen, wobei die Sitzung von Guggenheim über einen Live-Webcast verfügbar sein wird. Bei allen drei Konferenzen werden individuelle Meetings angeboten. Der Webcast von Guggenheim wird 90 Tage nach der Veranstaltung über die Website des Unternehmens zugänglich sein.
- None.
- None.
BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming investor conferences in November 2024.
- Praxis management will participate in a fireside chat at the Truist Securities BioPharma Symposium, taking place in the Lotte New York Palace Hotel in New York, NY on November 7, 2024 at 9:40am ET.
- Praxis management will also be participating in a fireside chat at the Guggenheim Securities Inaugural Healthcare Innovation Conference, taking place at the InterContinental Boston Hotel in Boston, MA on November 11, 2024 at 1:00pm ET. A live webcast of the fireside chat will be available through this link.
- Praxis management will also be participating in one-on-one meetings at the Jefferies London Healthcare Conference, taking place at the Waldorf Hilton Hotel in London, UK on November 20-21, 2024.
The Company will also be available for one-on-one meetings at the Truist and Guggenheim conferences. Interested investors should contact their respective corporate access representatives to request meetings.
The live webcast of Guggenheim fireside chat will also be available through the “Upcoming & Recent Events” page of the Investors + Media section of the company’s website at www.praxismedicines.com. Following this event, a replay will be posted, when available, to Praxis’ website on the “Events and Presentations” page under the investor section of the website for 90 days.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
FAQ
When is Praxis Precision Medicines (PRAX) presenting at the Truist Securities BioPharma Symposium in November 2024?
Which investor conferences is Praxis Precision Medicines (PRAX) attending in November 2024?
Will there be a webcast available for Praxis Precision Medicines' (PRAX) November 2024 conference presentations?
